Provided by Tiger Trade Technology Pte. Ltd.

NEWAMSTERDAM PHARMA CO NV

26.85
-1.0200-3.66%
Post-market: 27.160.3100+1.15%16:49 EDT
Volume:1.15M
Turnover:31.08M
Market Cap:3.21B
PE:-12.52
High:27.97
Open:27.80
Low:26.67
Close:27.87
52wk High:42.21
52wk Low:23.05
Shares:119.54M
Float Shares:92.51M
Volume Ratio:1.41
T/O Rate:1.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1442
EPS(LYR):-1.7211
ROE:-36.81%
ROA:-20.11%
PB:5.08
PE(LYR):-15.60

Loading ...

Newamsterdam Pharma Publishes Obicetrapib Alzheimer’s Prevention Research Presentation

Reuters
·
Jul 17

Vivani Stock Puts These Obesity And Diabetes Treatment Stocks On The Radar

Simply Wall St.
·
Jul 12

Did NewAmsterdam’s (NAMS) Alzheimer’s Biomarker Signal Just Recast Obicetrapib’s Dual-Disease Investment Narrative?

Simply Wall St.
·
Jul 09

Newamsterdam Pharma Grants 28,700 Inducement Share Options Priced at $35.17

Reuters
·
Jul 03

Newamsterdam Pharma to Present Obicetrapib Data for Early Alzheimer’s Prevention at AAIC 2026

Reuters
·
Jul 01

NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says

MT Newswires Live
·
Jun 30

RBC Raises Price Target on NewAmsterdam Pharma to $51 From $47, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Jun 30

Newamsterdam Pharma Chief Accounting Officer Louise Kooij Sells USD 1.21 Million in Shares

Reuters
·
Jun 25

NewAmsterdam Pharma posts real-world study presentation on high-intensity statin intolerance, adverse events

Reuters
·
Jun 17

Did Druckenmiller’s Spotlight and ESOP Shelf Just Reframe NewAmsterdam Pharma’s (NAMS) Obicetrapib Story?

Simply Wall St.
·
Jun 09

NewAmsterdam Pharma to present obicetrapib data at National Lipid Association Scientific Sessions

Reuters
·
Jun 03

NewAmsterdam Pharma shareholders approve 2026 employee stock purchase plan at annual meeting

Reuters
·
Jun 03

NewAmsterdam Pharma joins Jefferies Global Healthcare Conference fireside chat

Reuters
·
May 28

NewAmsterdam Pharma Chief Accounting Officer Louise Kooij reports $ 2.32 million share sale

Reuters
·
May 28

Why NewAmsterdam Pharma (NAMS) Is Up 29.7% After Detailing Obicetrapib Phase 3 And Launch Milestones

Simply Wall St.
·
May 11

Stock Track | NewAmsterdam Pharma Soars 5.19% Intraday on Anticipation of Upcoming Conference Presentations

Stock Track
·
May 11

Analysts Conflicted on These Healthcare Names: Treace Medical Concepts (TMCI), NewAmsterdam Pharma Company (NAMS) and LENSAR (LNSR)

TIPRANKS
·
May 11

NewAmsterdam Pharma to present at BofA Securities Health Care Conference

Reuters
·
May 11

Stock Track | NewAmsterdam Pharma Soars 5.31% Intraday on Guggenheim's Buy Rating

Stock Track
·
May 08

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 08